QVC pays for FTC violations
This article was originally published in The Tan Sheet
The U.S. District Court for the Eastern District of Pennsylvania orders the home shopping channel to pay $1.5 million in civil penalties and $6 million for consumer redress to the Federal Trade Commission for using deceptive advertising practices to market weight-loss supplements such as Bee-Alive Feel Good 90-Day System and For Women Only Zero Fat Ultra. The consent decree entered by the court March 4 further enjoins the Liberty Media subsidiary from again violating FTC's initial 2000 order, which bars QVC from making structure/function claims for dietary supplements without supportive scientific evidence. The commission filed its complaint against West Chester, Pa.-based QVC in 2004 (1"The Tan Sheet" March 29, 2004, In Brief)
You may also be interested in...
The home shopping channel violated a previous final order prohibiting QVC from using deceptive advertising practices to market weight-loss products, the FTC alleges in a March 24 complaint filed in Eastern Pennsylvania federal court. The commission maintains each airing of programs for Bee-Alive, For Women Only, Lipofactor Cellulite Target Lotion and Lite Bites a violation of the previous order. Programs touted testimonials from patients with cancer, lupus and multiple sclerosis who also claimed to have lost between 30 lbs and 140 lbs. In a same-day 1release, FTC points out the "claims for these products are not only unsubstantiated, but for some, scientifically impossible." Agency seeks monetary civil penalties, consumers redress and to permanently enjoin the Comcast subsidiary from violating the June 2000 order...
BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December.
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.